GlassScriptPhysician profile
Shelley C Ferrill
NPI 1801933205
$3,438.38
in general payments reported to CMS, 2019-2025
38 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $767 · 2021: $933 · 2022: $322 · 2023: $353 · 2024: $145 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $663.55 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $428.69 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $282.50 | 2019-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $211.03 | 2020-2022 | |
| Glaxosmithkline, LLC. | $193.57 | 2019-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Pfizer INC. | $175.71 | 2019-2024 | |
| Amarin Pharma, INC. | $164.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $155.70 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.49 | 2019-2024 | Synjardy, Jardiance |
| Amgen INC. | $112.94 | 2021-2025 | Repatha, Otezla, Otezla |
| Allergan, INC. | $84.32 | 2020 | |
| Adlon Therapeutics L.P. | $69.26 | 2019-2021 | |
| Abbott Laboratories | $60.43 | 2022-2023 | Freestyle Libre 3 |
| Eisai INC. | $57.98 | 2020-2021 | |
| Shire North American Group INC | $57.78 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelley Ferrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.